Development of a Novel Synchronous Spectrofluorimetric Method Coupled With Chemometric Modelling for Ultrasensitive Analysis of Tenofovir and Dolutegravir With Implication for Pharmacokinetic Studies
Authors:
- 6 January 2025
- journal article
- research article
- Published by Wiley in Luminescence
- Vol. 40 (1) , e70080
Abstract
This study introduces a novel synchronous spectrofluorimetry coupled with chemometric tools for the determination of tenofovir and dolutegravir antiretroviral drugs. Utilizing partial least squares regression (PLS) fine‐tuned by genetic algorithm as variable selection tool, the developed models demonstrate greater sensitivity, cost‐effectiveness, and reduced environmental impact compared to traditional HPLC methods. The model's validation was further confirmed using external validation in addition to QC samples as per ICH M10 guidelines, which yielded high accuracy ranged between 94.78% and 102.48% for tenofovir and 94.56% and 103.31% for dolutegravir, respectively. Additionally, the %CV values for within‐run precision were below 4%, while those for between‐run precision stayed under 6%, for tenofovir and dolutegravir, respectively. Hence, the developed models were adeptly applied to pharmacokinetic studies in a rat model, revealing slight changes in the tenofovir and dolutegravir plasma concentration profiles and half‐lives when administered in combination, highlighting possible drug interactions. Greenness analysis of this spectrofluorimetric approach using the AGREE tool further substantiates its advantages over conventional chromatographic techniques. Hence, this simple, rapid, and environmentally friendly analytical methodology presents a promising alternative for therapeutic drug monitoring and pharmacokinetic studies of tenofovir and dolutegravir antiretroviral drugs.Keywords
Funding Information
- Taif University (TU‐DSPP‐2025‐10)
This publication has 27 references indexed in Scilit:
- Environmentally benign first derivative synchronous spectrofluorimetry for the analysis of two binary mixtures containing duloxetine with avanafil or tadalafil in spiked plasma samplesLuminescence, 2024
- A highly sensitive micelle‐enhanced synchronous spectrofluorimetric determination of the recently approved co‐formulated drugs, bilastine and montelukast in pharmaceuticals and human plasma at nanogram levelsLuminescence, 2023
- HIV/AIDS Global Epidemic2023
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsJAMA, 2023
- Green Chemical Analysis and Sample Preparations2022
- Simultaneous determination of intracellular concentrations of tenofovir, emtricitabine, and dolutegravir in human brain microvascular endothelial cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS)Analytica Chimica Acta, 2019
- Green Analytical Chemistry2019
- Simultaneous determination of desloratadine and montelukast sodium using second‐derivative synchronous fluorescence spectrometry enhanced by an organized medium with applications to tablets and human plasmaLuminescence, 2014
- Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor DolutegravirClinical Pharmacokinetics, 2013
- Chemometrics2003